Table 3.

Key inputs parameters used to validate the CEPAC model with the community benefit incorporated against the HOPE model.

	Value
Parameter	MSM	PWID	Source
Number of PrEP-eligible individuals in 2016	2,206,379	386,209	[5, 36-38]
HIV prevalence, %	11.0	15.0	[39, 40]
HIV incidence, rate /100 PYs	0.6	0.9	Derived from [5]
PrEP efficacy, % (range)	73.0 (44.0-92.0)	49.0 (9.6-70.0)	[5, 17, 18]
PrEP uptake, % (range)	40.0 (20.0-60.0)	10.0 (5.0-15.0)	[5]
Linkage to care, %	73.4		[41]
Weighted average transmission rate within the primary cohort (rate/100 PYs)	3.3	7.1	Derived from incidence and prevalence
Transmission risk ratio by HIV RNA level (copies/mL)			[4]
>100,000	4.4
10,001-100,000	3.9
3,001-10,000	2.0
501-3,000	1.0 (reference)
≤500	0.1
Transmission risk ratio while in acute phase (vs. chronic)	5.3		[42]
Viral suppression on first-line ART (DTG) at 48 weeks, %	87.0		[14, 43]

CEPAC: Cost-Effectiveness of Preventing AIDS Complications model; HOPE: HIV Optimization and Prevention Economics model; DTG: dolutegravir; HIV: human immunodeficiency virus; mL: milliliter; MSM: men who have sex with men; PrEP: pre-exposure prophylaxis; PWID: people who inject drugs; PY: person-year.